Arrail Group Ltd. AI Stock Analysis
Want to see HK:6639 full AI Analyst Report?
Arrail Group Ltd. (6639) AI Stock Analysis
Arrail Group Ltd.
(HKEX:6639)
The score is driven primarily by improving fundamentals and solid cash generation, supporting a credible turnaround, but upside is constrained by still-thin profitability/low ROE and a slightly softer 2025 revenue trend. Technically the stock looks range-bound, and the high P/E without a dividend meaningfully weighs on the overall rating.
Arrail Group Ltd. (6639) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.03B
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- 31.1
- Beta (1Y)
- 1.00
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 3,296
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Arrail Group Ltd. Business Overview & Revenue Model
Company Description
Arrail Group Limited is a Chinese healthcare provider that manages a network of dental clinics and hospitals. It conducts its operations primarily through two brand identities: Arrail Dental and Rytime Dental. The company delivers a comprehensive sui...
Arrail Group Ltd. Financial Statement Overview
Summary
Turnaround is evident with profitability improving from 2022–2023 losses to modest profits in 2024–2025 and consistently positive operating/free cash flow. Offsetting this are slightly declining 2025 revenue, very thin net margin (~1.3%), and low ROE (~1.3%), which make results vulnerable to cost and volume swings.
Income Statement
62PositiveBalance Sheet
58NeutralCash Flow
72Positive| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.69B | 1.69B | 1.75B | 1.62B | 1.47B | 1.52B |
| Gross Profit | 342.09M | 342.09M | 392.68M | 336.56M | 247.08M | 364.42M |
| EBITDA | 314.83M | 312.65M | 322.35M | -417.14M | 87.85M | -300.84M |
| Net Income | 21.99M | 21.99M | 17.16M | -701.03M | -219.91M | -599.42M |
Balance Sheet | ||||||
| Total Assets | 3.16B | 3.16B | 3.25B | 2.99B | 3.06B | 2.35B |
| Cash, Cash Equivalents and Short-Term Investments | 1.09B | 1.09B | 1.10B | 1.26B | 937.53M | 727.31M |
| Total Debt | 1.03B | 1.03B | 1.05B | 890.67M | 955.68M | 1.03B |
| Total Liabilities | 1.38B | 1.38B | 1.42B | 1.38B | 1.37B | 4.81B |
| Stockholders Equity | 1.71B | 1.71B | 1.76B | 1.56B | 1.61B | -2.50B |
Cash Flow | ||||||
| Free Cash Flow | 181.98M | 172.69M | 184.21M | 108.63M | 23.50M | 213.50M |
| Operating Cash Flow | 234.02M | 231.14M | 276.65M | 224.28M | 131.66M | 242.87M |
| Investing Cash Flow | -182.75M | -153.52M | -176.00M | -203.94M | -342.44M | 61.75M |
| Financing Cash Flow | -188.74M | -206.84M | -106.96M | 380.86M | -280.35M | 217.51M |
Arrail Group Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6639, the sentiment is Positive. The current price of 1.83 is below the 20-day moving average (MA) of 1.83, below the 50-day MA of 1.83, and below the 200-day MA of 1.83, indicating a bullish trend. The MACD of 0.00 indicates Positive momentum. The RSI at is Neutral, neither overbought nor oversold. The STOCH value of 30.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6639.
Arrail Group Ltd. Peers Comparison
Overall Rating
HK:237378Outperform
HK:330976Outperform
HK:221970Outperform
HK:663960Neutral
HK:184655Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | HKD 4.53B | 9.59 | 31.63% | 3.99% | 22.71% | 43.58% | |
| 76Outperform | HKD 1.21B | 11.22 | 5.57% | 3.17% | 4.75% | ― | |
| 70Outperform | HKD 1.65B | 8.32 | 6.97% | 10.31% | 3.85% | -1.23% | |
| 60Neutral | HKD 1.03B | 31.11 | 1.27% | ― | ― | ― | |
| 55Neutral | HKD 620.36M | 251.95 | 0.20% | 2.27% | 20.54% | -96.74% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6639 | Arrail Group Ltd. | 1.83 | 0.20 | 12.21% | |
| HK:1846 | EuroEyes International Eye Clinic Limited | 1.88 | -1.28 | -40.56% | |
| HK:2219 | Chaoju Eye Care Holdings Ltd. | 2.33 | -0.02 | -0.68% | |
| HK:2279 | Yonghe Medical Group Co., Ltd. | 2.14 | 0.39 | 22.22% | |
| HK:2373 | Beauty Farm Medical & Health Industry, Inc. | 17.64 | -9.75 | -35.61% | |
| HK:3309 | C-MER Eye Care Holdings Limited | 0.93 | -0.75 | -44.54% |
Arrail Group Ltd. Corporate Events
Arrail delays interim results as probe and auditor change drag on
Arrail Group Limited has provided a quarterly update on the ongoing independent investigation into historical loans, repayments and related payments, noting that investigators have substantially completed major work streams but have faced delays due...
Arrail Replaces PwC as Auditor Amid Delayed Interim Review and Ongoing Probe
Arrail Group Limited has announced the resignation of PricewaterhouseCoopers as its auditor, following delays in the review of the group’s interim financial information for the six months ended September 30, 2025 and ongoing independent investigation...
Arrail Group Extends Interim Results Delay Amid Forensic Probe Into Related Transactions
Arrail Group Limited has announced further delays to the publication of its interim results for the six months ended 30 September 2025 and the dispatch of its 2025 interim report, and confirmed that trading in its shares will remain suspended. The de...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Mar 24, 2026
